Disc Medicine ( (IRON) ) has shared an update.
Disc Medicine has secured a $200 million non-dilutive debt financing from Hercules Capital to enhance its financial flexibility and support the development of its hematology pipeline. This funding will aid key projects, including a potential confirmatory study of bitopertin and other clinical trials. The loan offers up to 60 months of interest-only payments, providing Disc with strategic options to advance its novel treatments for hematologic diseases.
For detailed information about IRON stock, go to TipRanks’ Stock Analysis page.